Literature DB >> 33657413

SARM1 is a metabolic sensor activated by an increased NMN/NAD+ ratio to trigger axon degeneration.

Matthew D Figley1, Weixi Gu2, Jeffrey D Nanson2, Yun Shi3, Yo Sasaki4, Katie Cunnea5, Alpeshkumar K Malde3, Xinying Jia6, Zhenyao Luo2, Forhad K Saikot2, Tamim Mosaiab3, Veronika Masic3, Stephanie Holt3, Lauren Hartley-Tassell3, Helen Y McGuinness2, Mohammad K Manik2, Todd Bosanac7, Michael J Landsberg2, Philip S Kerry5, Mehdi Mobli6, Robert O Hughes7, Jeffrey Milbrandt8, Bostjan Kobe9, Aaron DiAntonio10, Thomas Ve11.   

Abstract

Axon degeneration is a central pathological feature of many neurodegenerative diseases. Sterile alpha and Toll/interleukin-1 receptor motif-containing 1 (SARM1) is a nicotinamide adenine dinucleotide (NAD+)-cleaving enzyme whose activation triggers axon destruction. Loss of the biosynthetic enzyme NMNAT2, which converts nicotinamide mononucleotide (NMN) to NAD+, activates SARM1 via an unknown mechanism. Using structural, biochemical, biophysical, and cellular assays, we demonstrate that SARM1 is activated by an increase in the ratio of NMN to NAD+ and show that both metabolites compete for binding to the auto-inhibitory N-terminal armadillo repeat (ARM) domain of SARM1. We report structures of the SARM1 ARM domain bound to NMN and of the homo-octameric SARM1 complex in the absence of ligands. We show that NMN influences the structure of SARM1 and demonstrate via mutagenesis that NMN binding is required for injury-induced SARM1 activation and axon destruction. Hence, SARM1 is a metabolic sensor responding to an increased NMN/NAD+ ratio by cleaving residual NAD+, thereby inducing feedforward metabolic catastrophe and axonal demise.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ARM domain; NADase; TIR domain; X-ray crystallography; allostery; cryo-EM; nicotinamide riboside

Mesh:

Substances:

Year:  2021        PMID: 33657413      PMCID: PMC8174188          DOI: 10.1016/j.neuron.2021.02.009

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  97 in total

1.  Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy.

Authors:  Peter B Rosenthal; Richard Henderson
Journal:  J Mol Biol       Date:  2003-10-31       Impact factor: 5.469

2.  Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald.

Authors:  Romelia Salomon-Ferrer; Andreas W Götz; Duncan Poole; Scott Le Grand; Ross C Walker
Journal:  J Chem Theory Comput       Date:  2013-08-20       Impact factor: 6.006

3.  Image-based screening identifies novel roles for IkappaB kinase and glycogen synthase kinase 3 in axonal degeneration.

Authors:  Josiah Gerdts; Yo Sasaki; Bhupinder Vohra; Jayne Marasa; Jeffrey Milbrandt
Journal:  J Biol Chem       Date:  2011-06-17       Impact factor: 5.157

4.  The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration.

Authors:  Kow Essuman; Daniel W Summers; Yo Sasaki; Xianrong Mao; Aaron DiAntonio; Jeffrey Milbrandt
Journal:  Neuron       Date:  2017-03-22       Impact factor: 17.173

5.  MolProbity: More and better reference data for improved all-atom structure validation.

Authors:  Christopher J Williams; Jeffrey J Headd; Nigel W Moriarty; Michael G Prisant; Lizbeth L Videau; Lindsay N Deis; Vishal Verma; Daniel A Keedy; Bradley J Hintze; Vincent B Chen; Swati Jain; Steven M Lewis; W Bryan Arendall; Jack Snoeyink; Paul D Adams; Simon C Lovell; Jane S Richardson; David C Richardson
Journal:  Protein Sci       Date:  2017-11-27       Impact factor: 6.725

6.  Structural Evidence for an Octameric Ring Arrangement of SARM1.

Authors:  Michael Sporny; Julia Guez-Haddad; Mario Lebendiker; Valeria Ulisse; Allison Volf; Carsten Mim; Michail N Isupov; Yarden Opatowsky
Journal:  J Mol Biol       Date:  2019-07-03       Impact factor: 5.469

7.  SARM1-specific motifs in the TIR domain enable NAD+ loss and regulate injury-induced SARM1 activation.

Authors:  Daniel W Summers; Daniel A Gibson; Aaron DiAntonio; Jeffrey Milbrandt
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-26       Impact factor: 11.205

8.  Pharmacological bypass of NAD+ salvage pathway protects neurons from chemotherapy-induced degeneration.

Authors:  Hui-Wen Liu; Chadwick B Smith; Mark S Schmidt; Xiaolu A Cambronne; Michael S Cohen; Marie E Migaud; Charles Brenner; Richard H Goodman
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-26       Impact factor: 11.205

9.  PDBsum: Structural summaries of PDB entries.

Authors:  Roman A Laskowski; Jagoda Jabłońska; Lukáš Pravda; Radka Svobodová Vařeková; Janet M Thornton
Journal:  Protein Sci       Date:  2017-10-27       Impact factor: 6.725

10.  Small Molecule SARM1 Inhibitors Recapitulate the SARM1-/- Phenotype and Allow Recovery of a Metastable Pool of Axons Fated to Degenerate.

Authors:  Robert O Hughes; Todd Bosanac; Xianrong Mao; Thomas M Engber; Aaron DiAntonio; Jeffrey Milbrandt; Rajesh Devraj; Raul Krauss
Journal:  Cell Rep       Date:  2021-01-05       Impact factor: 9.423

View more
  49 in total

Review 1.  SARM1 can be a potential therapeutic target for spinal cord injury.

Authors:  Qicheng Lu; Benson O A Botchway; Yong Zhang; Tian Jin; Xuehong Liu
Journal:  Cell Mol Life Sci       Date:  2022-02-28       Impact factor: 9.261

2.  Nicotinic acid mononucleotide is an allosteric SARM1 inhibitor promoting axonal protection.

Authors:  Yo Sasaki; Jian Zhu; Yun Shi; Weixi Gu; Bostjan Kobe; Thomas Ve; Aaron DiAntonio; Jeffrey Milbrandt
Journal:  Exp Neurol       Date:  2021-08-14       Impact factor: 5.330

3.  Neurotoxins subvert the allosteric activation mechanism of SARM1 to induce neuronal loss.

Authors:  Tong Wu; Jian Zhu; Amy Strickland; Kwang Woo Ko; Yo Sasaki; Caitlin B Dingwall; Yurie Yamada; Matthew D Figley; Xianrong Mao; Alicia Neiner; A Joseph Bloom; Aaron DiAntonio; Jeffrey Milbrandt
Journal:  Cell Rep       Date:  2021-10-19       Impact factor: 9.423

4.  Selective inhibitors of SARM1 targeting an allosteric cysteine in the autoregulatory ARM domain.

Authors:  Hannah C Feldman; Elisa Merlini; Carlos Guijas; Kristen E DeMeester; Evert Njomen; Ellen M Kozina; Minoru Yokoyama; Ekaterina Vinogradova; Holly T Reardon; Bruno Melillo; Stuart L Schreiber; Andrea Loreto; Jacqueline L Blankman; Benjamin F Cravatt
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-22       Impact factor: 12.779

Review 5.  Axon Biology in ALS: Mechanisms of Axon Degeneration and Prospects for Therapy.

Authors:  Michael P Coleman
Journal:  Neurotherapeutics       Date:  2022-10-07       Impact factor: 6.088

6.  Mitochondrial Localization of SARM1 in Acrylamide Intoxication Induces Mitophagy and Limits Neuropathy.

Authors:  Shuai Wang; Mingxue Song; Hui Yong; Cuiqin Zhang; Kang Kang; Zhidan Liu; Yiyu Yang; Zhengcheng Huang; Shu'e Wang; Haotong Ge; Xiulan Zhao; Fuyong Song
Journal:  Mol Neurobiol       Date:  2022-09-29       Impact factor: 5.682

7.  Genetic inactivation of SARM1 axon degeneration pathway improves outcome trajectory after experimental traumatic brain injury based on pathological, radiological, and functional measures.

Authors:  Donald V Bradshaw; Andrew K Knutsen; Alexandru Korotcov; Genevieve M Sullivan; Kryslaine L Radomski; Bernard J Dardzinski; Xiaomei Zi; Dennis P McDaniel; Regina C Armstrong
Journal:  Acta Neuropathol Commun       Date:  2021-05-17       Impact factor: 7.801

Review 8.  A Novel NAD Signaling Mechanism in Axon Degeneration and its Relationship to Innate Immunity.

Authors:  Eleanor L Hopkins; Weixi Gu; Bostjan Kobe; Michael P Coleman
Journal:  Front Mol Biosci       Date:  2021-07-08

Review 9.  SARM1 signaling mechanisms in the injured nervous system.

Authors:  Shilpa Sambashivan; Marc R Freeman
Journal:  Curr Opin Neurobiol       Date:  2021-06-25       Impact factor: 7.070

Review 10.  Evolving concepts in NAD+ metabolism.

Authors:  Claudia C S Chini; Julianna D Zeidler; Sonu Kashyap; Gina Warner; Eduardo Nunes Chini
Journal:  Cell Metab       Date:  2021-04-29       Impact factor: 31.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.